| Followers | 68 |
| Posts | 9400 |
| Boards Moderated | 0 |
| Alias Born | 04/05/2016 |
Wednesday, February 18, 2026 8:17:35 AM
You keep using the word “shut down” as if it were an enforcement action. It wasn’t.
There was an initial academic phase.
There is now a regulatory review phase with DCGI for continuation and expansion.
That’s not a “shutdown.” That’s how clinical programs transition between stages.
You also keep claiming there are “no pending applications.” The company publicly stated in its Feb 3 update that DCGI clearance is anticipated this quarter and that an IDE submission update is forthcoming.
If there were no pending regulatory interaction, they wouldn’t be referencing ongoing review.
Repeating “no trials anywhere” while the company is in active regulatory review is like saying “there’s no flight” while the plane is at the gate awaiting clearance.
You’re just a serial liar and troll whose only agenda is to spread BS.
Pity the fool who listens to your habitual lies and fabrications.
There was an initial academic phase.
There is now a regulatory review phase with DCGI for continuation and expansion.
That’s not a “shutdown.” That’s how clinical programs transition between stages.
You also keep claiming there are “no pending applications.” The company publicly stated in its Feb 3 update that DCGI clearance is anticipated this quarter and that an IDE submission update is forthcoming.
If there were no pending regulatory interaction, they wouldn’t be referencing ongoing review.
Repeating “no trials anywhere” while the company is in active regulatory review is like saying “there’s no flight” while the plane is at the gate awaiting clearance.
You’re just a serial liar and troll whose only agenda is to spread BS.
Pity the fool who listens to your habitual lies and fabrications.
Recent RDGL News
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 03/06/2026 05:15:04 AM
- Form 1-A/A - Offering Statement [Regulation A]: [Amend] • Edgar (US Regulatory) • 03/04/2026 04:48:52 PM
- Vivos Inc. Diversifies Manufacturing Base with Planned U.S. and International Production Sites • GlobeNewswire Inc. • 02/17/2026 01:30:00 PM
- Vivos Inc. Announces Significant Progress Toward FDA Investigational Device Exemption (IDE) Submission for RadioGel® Precision Radionuclide Therapy™ • GlobeNewswire Inc. • 02/10/2026 01:30:00 PM
- Vivos Inc Updates Human Therapy Progress in India • GlobeNewswire Inc. • 02/03/2026 01:30:00 PM
- Vivos Inc. Strengthens Patent Protection with New U.S. Patent Issuance and PRECISIONGEL™ Trademark Approvals • GlobeNewswire Inc. • 01/28/2026 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2026 04:06:21 PM
- Vivos Inc Summarizes Progress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 05:56:08 PM
- Vivos Inc Summarzes Preogress in its Animal Therapy Division • GlobeNewswire Inc. • 12/22/2025 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/09/2025 09:00:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/21/2025 12:34:42 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/12/2025 11:08:03 AM
- Vivos Inc. Issues Shareholder Update Letter • GlobeNewswire Inc. • 11/06/2025 01:30:00 PM
- Vivos Inc. Strengthens Strategic Collaboration with Exubrion Therapeutics • GlobeNewswire Inc. • 10/29/2025 12:30:00 PM
- Vivos Inc. Retains Top FDA Regulatory Expert Dr. John J. Smith, M.D., J.D., to Support IDE Submission for RadioGel® • GlobeNewswire Inc. • 10/27/2025 12:30:00 PM
- Vivos Inc Board Authorizes Vivos Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 05:46:00 PM
- Vivos Inc Board Authorizes Vivios Inc to Establish a Corporate Entity in India • GlobeNewswire Inc. • 09/29/2025 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2025 08:01:35 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2025 07:32:46 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2025 09:14:29 PM
